Insider Ledger
Anaptysbio, Inc. (ANAB) insider buying and SEC filings
Anaptysbio, Inc. · CIK 1370053
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Jun 30
- Former names
- ANAPTYSBIO INC; ANAPTYS BIOSCIENCES INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$5.3M
Planned sales (10b5-1)
$4.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Hollings Renton (Director) sold 5,000 shares at about $49.87 ($249K), marked as a 10b5-1 plan trade. Holdings down 31% to 10,995 shares. | SEC filing Filed Oct 2, 2026, 5:47 PM ET |
| Mar 30, 2026 | Sale | John P. Schmid (Director) sold 20,645 shares at about $56.11 ($1.2M). Holdings down 39% to 31,622 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 1, 2026 |
| Mar 27, 2026 | Sale | Daniel Faga (CEO and Director) sold 17,679 shares at about $61.61 ($1.1M). Holdings down 3% to 495,965 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 27, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Eric J. Loumeau (Chief Legal Officer) sold 10,000 shares at $54.00 ($540K), marked as a 10b5-1 plan trade. Holdings down 44% to 12,835 shares. | SEC filing Filed Feb 13, 2026 |
| Jan 8, 2026 | Sale | Paul F. Lizzul (Chief Medical Officer) sold 3,650 shares at $44.71 ($163K). Holdings down 8% to 42,088 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 9, 2026 |
| Jan 8, 2026 | Sale | Daniel Faga (CEO and Director) sold 14,281 shares at $44.71 ($639K). Holdings down 3% to 479,344 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 9, 2026 |
| Jan 8, 2026 | Sale | Dennis Mulroy (CFO) sold 2,515 shares at $44.71 ($112K). Holdings down 10% to 21,852 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 9, 2026 |
| Jan 8, 2026 | Sale | Eric J. Loumeau (Chief Legal Officer) sold 2,210 shares at $44.71 ($99K). Holdings down 15% to 12,835 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 9, 2026 |
| Jan 7, 2026 | Sale | Paul F. Lizzul (Chief Medical Officer) sold 2,235 shares at $45.11 ($101K). Holdings down 6% to 37,213 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 7, 2026 | Sale | Daniel Faga (CEO and Director) sold 9,202 shares at $45.11 ($415K). Holdings down 2% to 466,787 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 7, 2026 | Sale | Dennis Mulroy (CFO) sold 1,908 shares at $45.11 ($86K). Holdings down 10% to 17,667 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Eric J. Loumeau (Chief Legal Officer) sold 7,622 shares at about $45.68 ($348K), marked as a 10b5-1 plan trade. Holdings down 45% to 9,157 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 7, 2026 | Sale | Eric J. Loumeau (Chief Legal Officer) sold 2,017 shares at $45.11 ($91K). Holdings down 11% to 16,779 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 5, 2026 | Sale | Paul F. Lizzul (Chief Medical Officer) sold 4,219 shares at $43.26 ($183K). Holdings down 11% to 33,303 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Jan 5, 2026 | Sale | Daniel Faga (CEO and Director) sold 15,309 shares at $43.26 ($662K). Holdings down 3% to 458,139 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Jan 5, 2026 | Sale | Dennis Mulroy (CFO) sold 3,363 shares at $43.26 ($145K). Holdings down 19% to 14,330 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Jan 5, 2026 | Sale | Eric J. Loumeau (Chief Legal Officer) sold 2,983 shares at $43.26 ($129K). Holdings down 18% to 13,251 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Dec 23, 2025 | Sale | J. Anthony Ware (Director) sold 3,900 shares at $49.58 ($193K). Holdings down 29% to 9,630 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 23, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Paul F. Lizzul (Chief Medical Officer) sold 1,500 shares at $50.00 ($75K), marked as a 10b5-1 plan trade. Holdings down 5% to 26,967 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Dennis Mulroy (CFO) sold 10,000 shares at $50.00 ($500K), marked as a 10b5-1 plan trade. Holdings down 52% to 9,401 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Eric J. Loumeau (Chief Legal Officer) sold 10,000 shares at $51.00 ($510K), marked as a 10b5-1 plan trade. Holdings down 53% to 8,947 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Dennis Mulroy (CFO) sold 15,725 shares at about $44.86 ($705K), marked as a 10b5-1 plan trade. Holdings down 63% to 9,401 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16–18, 2025 | Planned (10b5-1) | Eric J. Loumeau (Chief Legal Officer) sold 22,641 shares between Dec 16, 2025 and Dec 18, 2025 at about $45.38 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 72% to 8,947 shares. | SEC filing Filed Dec 18, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ANAB in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.